146 related articles for article (PubMed ID: 18505128)
1. [Clinical evaluation of efficacy and safety of nateglinide in the treatment of type 2 diabetes].
Li YX; Ding GX; Li QF; Chen L; Hu GL; Ji QH; Wang SJ; Guo Y; Luo R; Hou WK; Wang PN; Zhang NY; Zhang YP; Wang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Apr; 30(2):211-3. PubMed ID: 18505128
[TBL] [Abstract][Full Text] [Related]
2. Study of nateglinide in Japan: long-term treatment of patients with type 2 diabetes.
Taki H; Maki T; Iso T; Iwamoto K; Kajiura T
Adv Ther; 2006; 23(2):307-24. PubMed ID: 16751163
[TBL] [Abstract][Full Text] [Related]
3. Postmarketing study of nateglinide in Japan: treatment of medication-naïve patients with type 2 diabetes.
Taki H; Maki T; Iso T; Tanabe S; Kajiura T
Adv Ther; 2005; 22(6):621-35. PubMed ID: 16510379
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
5. Postmarketing surveillance study of nateglinide in Japan.
Taki H; Maki T; Iso T; Iwamoto K; Kajiura T
Adv Ther; 2005; 22(5):513-26. PubMed ID: 16418160
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.
Raskin P; Klaff L; McGill J; South SA; Hollander P; Khutoryansky N; Hale PM;
Diabetes Care; 2003 Jul; 26(7):2063-8. PubMed ID: 12832314
[TBL] [Abstract][Full Text] [Related]
7. Mealtime glucose regulation by nateglinide in type-2 diabetes mellitus.
Walter YH; Spratt DI; Garreffa S; McLeod JF
Eur J Clin Pharmacol; 2000 May; 56(2):129-33. PubMed ID: 10877006
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of efficacy between nateglinide and repaglinide in treating type 2 diabetes: a randomized controlled double-blind clinical trial].
Li JW; Tian HM; Yu HL; Zhang XX; Zhao GZ; Wang JN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 Mar; 36(2):267-70. PubMed ID: 15807285
[TBL] [Abstract][Full Text] [Related]
9. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia.
Saloranta C; Hershon K; Ball M; Dickinson S; Holmes D
J Clin Endocrinol Metab; 2002 Sep; 87(9):4171-6. PubMed ID: 12213867
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a new insulinotropic agent by using an innovative technology: efficacy and safety of nateglinide determined by continuous glucose monitoring.
Abrahamian H; Francesconi M; Loiskandl A; Dzien A; Prager R; Weitgasser R
Diabetes Technol Ther; 2004 Feb; 6(1):31-7. PubMed ID: 15000767
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the effects of nateglinide on postprandial glycemia in patients with type 2 diabetes mellitus: a multicenter, multinational, non-randomized, non-controlled Latin American study.
Islas-Andrade S; Revilla-Monsalve MC; Martínez de Hurtado E; Chacín LF; Caminos QR; Yupanqui H; López G; de la Torre W;
Pharmacology; 2003 Jun; 68(2):89-95. PubMed ID: 12711836
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus.
Fonseca VA; Kelley DE; Cefalu W; Baron MA; Purkayastha D; Nestler JE; Hsia S; Gerich JE
Metabolism; 2004 Oct; 53(10):1331-5. PubMed ID: 15375790
[TBL] [Abstract][Full Text] [Related]
14. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes.
Schwarz SL; Gerich JE; Marcellari A; Jean-Louis L; Purkayastha D; Baron MA
Diabetes Obes Metab; 2008 Aug; 10(8):652-60. PubMed ID: 17941876
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide versus repaglinide for type 2 diabetes mellitus in China.
Li C; Xia J; Zhang G; Wang S; Wang L
Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841
[TBL] [Abstract][Full Text] [Related]
16. Nateglinide therapy for type 2 diabetes mellitus.
Levien TL; Baker DE; Campbell RK; White JR
Ann Pharmacother; 2001 Nov; 35(11):1426-34. PubMed ID: 11724096
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
Schatz H; Schoppel K; Lehwalder D; Schandry R
Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes.
Israel MK; Istvan E; Baron MA
Vasc Health Risk Manag; 2008; 4(6):1167-78. PubMed ID: 19337530
[TBL] [Abstract][Full Text] [Related]
19. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide and repaglinide.
Vlckova V; Cornelius V; Kasliwal R; Wilton L; Shakir SA
Drug Saf; 2009; 32(5):409-18. PubMed ID: 19419235
[TBL] [Abstract][Full Text] [Related]
20. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
